Today, we're seeing the beginning of the next great biotech boom... and it has nothing to do with COVID-19.
That's because researchers are finally re-thinking how we deal with mental health.
According to Reuters, mental health disorders is projected to be costing the world $16 trillion in the 20 year period from 2010 to 2030.
And at the moment, we're left with hundreds of flawed solutions.
In fact, some are so harmful that less than 50% of patients that are prescribed these medications actually end up taking them.
That's the reason big-time investors like PayPal co-founder Peter Thiel, Shark Tank star Kevin O'Leary, and pot stock dynamo Bruce Linton are said to be investing money into the psychedelics space.
And they are not alone.
Even some of the biggest pharmaceutical companies like Johnson & Johnson and $195 billion giant Abbvie are moving into this burgeoning market.
At the same time, world-class institutions are racing ahead with groundbreaking research into the potential benefits of psychedelics.
That includes respected medical organizations like Johns Hopkins University, University of Toronto, Imperial College, and King's College.
And one little-known biotech company could be set to take this space by storm.
HAVN Life is aiming to provide a reliable source of psilocybin for the hundreds of studies that are being carried out in this burgeoning industry.
Supplying the Anticipated Boom
By delivering high-quality, naturally-derived psilocybin directly to researchers making these breakthroughs, they could serve a critical role.
We think it's like investing in Microsoft in the early 90s, as they delivered the software the Tech Boom was all built upon.
And for HAVN Life, being a leading supplier could also mean another major benefit.
Unlike pharmaceutical companies that will have to wait 3 to 5 years for clinical studies to wrap up and await FDA approval before ever seeing revenue...
They might be able to drive revenue long before that point if they make sales directly to these research organizations.
According to reports, they've already developed partnerships with a leading veterans’ organization in Canada for Phase 1 pre-clinical research.
That could set HAVN Life up to develop creative new formulations to potentially help treat veterans with PTSD and other trauma-related disorders.
We think this is a huge opportunity, and it's only getting bigger.
The U.S. military has already spent $14 million to study the effects of psilocybin on posttraumatic stress disorder (PTSD) in veterans.
So with tens of millions of dollars being spent by government agencies, HAVN Life might have spotted an incredible opportunity.
That kind of foresight is part of what we think helped them land a coveted spot on the first psychedelics ETF as well.
In our view, this is a huge accomplishment that could put them alongside Big Pharma giants like Johnson & Johnson and Abbvie, along with other billion-dollar companies in this growing space.
So what makes HAVN Life's product so unique?
Standing Out from the Competition
With millions of people suffering from mental health conditions, Big Pharma has a serious problem.
Despite these conditions having a devastating effect on these people's lives, many have made clear they have no interest in taking the lab-made medications Big Pharma is peddling.
So it's no wonder many people are objecting to synthetic psilocybin too.
Synthetic products leave researchers with only the psilocybin molecule, leaving out the hundreds of other compounds that are found in these "magic mushrooms."
These are the compounds that have been part of native ceremonies and ancient rituals for thousands of years, taken by simply drying the mushrooms and making tea.
With HAVN Life (CSE: HAVN; OTC: HAVLF) committed to providing naturally derived mushroom extracts, this could give them a clear leg up against other suppliers making their products under microscopes in the labs.
It might allow HAVN Life to provide a safe supply of these natural products to researchers and formulators alike.
They’re reported to be the first company to be granted a Section 56 exemption from Health Canada, allowing them to work with psilocybin in a lab.
And this important announcement has given them a necessary ingredient to start building protocols for their proposed GMP-compliant facility.
But HAVN Life may have given investors another reason to be excited, as they're apparently moving up the starting line to reach revenue even sooner.
Entering Another Booming Market
Today, 74% of adults take supplements on a regular basis, whether that's vitamins or other natural supplements.
That’s why the vitamins and minerals markets have really increased in recent years.
With people more focused on their health now than ever before, this led to the beginning of HAVN Life’s retail branch.
HAVN Life says it has developed a range of 7 natural mushroom-based health products that are set to launch before the end of this quarter.
And to launch this line, they apparently won't have to worry about the kind of regulatory red tape that most pharmaceutical companies work through.
That's because, under Health Canada's and the FDA's guidelines, the products would fall under the same rules as other herbs and supplements like melatonin and ginger.
Given that mushrooms are the second-fastest-growing natural health supplement, HAVN Life may have uncovered a golden opportunity while this area is still underserved in the markets.
The company says their new line of health products is designed to help support memory, focus, energy, and overall brain functioning to help people achieve peak performance throughout their daily lives.
And they've reportedly already developed their plan to roll it out to a broad audience across North America.
HAVN Life (CSE: HAVN; OTC: HAVLF) says it plans to promote these products through traditional retailers this year after announcing a significant distribution deal with Nesters Market in the Vancouver area.
That would put their mushroom-based line in 11 premium grocery stores, which are part of the Pattison Group, one of the largest retailers in Canada.
This could give them a foot in the door that they hope to leverage to expand throughout Canada as the year goes on.
But they won't rely on just in-store purchases.
As online shopping has surged in recent years, HAVN Life plans to build out its own e-commerce website to sell direct-to-consumer as well.
With these pieces in place, HAVN Life plans to expand its new line throughout Canada in 2021 and into the United States next year.
The momentum looks to be building for Havn Retail, but on the other side of the business, the pace could be quickening at Havn Labs as well.
Revenue Potential Within Reach
HAVN Life recently announced they have established a team on the ground in Jamaica, helping build up the lab where they can legally grow mushrooms and do extractions on-site.
This might put them ahead of many others who are still struggling to develop GMP-compliant facilities where they can make this magic happen.
With this announcement, we think they’ve checked off another major box and become that much closer to becoming a supplier in this growing corner of the biotech market.
HAVN Life says it already received their first research license from Health Canada last year, which gives them the thumbs up to research and develop psychedelic compounds.
It looks like all they need to get started now is to secure their dealer's license, allowing them to supply and sell regulated compounds.
Assuming they receive the go-ahead for this just as they did for the research license, they could be set to supply naturally derived psilocybin for clinical research studies before we know it.
We think that puts them in a position to become a leader in this new biotech market trend.
And at the moment, we believe HAVN Life is significantly undervalued.
Other players in this market are sitting on multi-million and billion-dollar market caps as this industry takes off.
MindMed boasts a market cap of $737 million.
And Compass Therapeutics is currently valued at a market cap of $2.4 billion.
That's why we think this may be the most exciting time for HAVN Life, as they appear set to help build the groundwork for what could become the next great biotech boom.
Psychedelics Could Be Bigger Than The Cannabis Boom
Cannabis exploded onto the scene on the first round of legalization, with many companies earning investors significant returns in that time.
Tilray Inc. (NASDAQ:TLRY) is one of Canada’s most established and profitable marijuana companies. And as President-Elect Joe Biden continues to pursue efforts to legalize marijauana, and a new string of localized marijuana legalization hits the United States, investors are watching established giants like Tilray closely into the next stage of the cannabis boom.
CEO Brendan Kennedy noted, "Adult-use legalization in New Jersey is likely to have a domino effect on the states of New York, Pennsylvania, and Connecticut, as elected officials are worried that their residents will go to New Jersey to purchase product and thereby not generate tax dollars in their home state.” Kennedy also noted that the pandemic could act as a catalyst in speeding up legalization, as well.
While Tilray’s share price took a hit in March of 2020 due to the ongoing COVID-19 pandemic, its recent earnings reports were significantly less disappointing than many analysts had expected. Thanks to this, Tilray has seen a bit of a turnaround, with its share price rising to a high of $29 in early 2021 before settling at today's levels.
Cronos Group (NASDAQ:CRON, TSX: CRON) is another cannabis giant that took a hit during the first half of 2020. Since then, however, it has made a significant comeback, recapturing investor interest thanks to renewed sector-wide optimism. The bounce back in investor sentiment has also been reflected in its share price. In early 2021, Cronos saw its share price soar to $15 on the Biden-legalization hype, but it has settled down since. That doesn’t mean it’s not poised for another surge once the Administration gets past COVID and onto some of its larger campaign promises, including marijuana legalization.
Despite being primarily an equity investor, Cronos has also been making some major moves in its dealmaking in recent years, locking in landmark agreements with some of the hottest names in the burgeoning cannabis sector. Because of its ambitious plans and history of success, it has drawn the attention of some of the world’s most influential companies, including the company behind Marlboro, Big Tobacco megalith Altria Group, which purchased a 45% stake in the company in 2018 for a total of $2.4 billion.
CEO of Cronos Group, Kurt Schmidt has kept his head up despite the tough year, noting in the most recent earnings call that “Our [Cronos Group] value will come from technology breakthroughs and branded sales that will help establish relationships with our consumers. There's top-tier talent across this organization and I'm excited to lead this impressive team into the next phase of growth.”
As the world’s third-largest marijauana company, Aphria Inc (NASDAQ:APHA, TSX:APHA), an Ontario-based marijuana giant currently has operations in 10 countries and distributes legal medical marijuana across the planet. And thanks to its unique approach to this emerging market, Aphria has proven itself to be resilient even amidst the global pandemic that has left many of its peers hurting.
One way Aphria has set itself apart in this turbulent market is through its acquisition of SweetWater Brewing, one of America’s largest craft breweries. Aphiria’s big gamble on SweetWater is an integral part of its big picture plan to capitalize on the booming ‘lifestyle’ market. A market that has grown in popularity through the rise of craft beers and specialized marijuana blends.
Aphria Chairman and CEO Irwin Simon explained, “We will establish and grow our U.S. presence through SweetWater's robust, profitable platform of craft brewing innovation, manufacturing, marketing and distribution expertise. At the same time, we will build brand awareness for our adult-use cannabis brands, Broken Coast, Good Supply, Riff and Solei, through our participation in the growing $29 billion craft brew market in the U.S. ahead of potential future state or federal cannabis legalization.”
Aurora Cannabis (NYSE:ACB, TSX:ACB) is another giant in Canada’s cannabis scene. After years of carefully planned moves and with the help of an industry-leading management team, Aurora has carved out its position as one of the most exciting players in the booming marijuana industry. It’s a veteran in the market, and as such, Aurora has been able to close a number of high-profile deals, including the acquisitions of CanniMed and MedReleaf. But that was just the beginning of its aggressive expansion strategy.
In November of 2020, Aurora announced a massive deal to supply marijuana to Cantek, a leader in Israel’s booming medical market. The landmark deal would include deliveries totalling to a minimum of 4,000 kgs of bulk dried flower every year. "We are excited about our strategic relationship with Cantek, a leader in the Israeli market. This Agreement provides Aurora with a great opportunity to expand our medical cannabis brand and industry leading science in one of our key international markets of focus,” explained Miguel Martin, Chief Executive Officer of Aurora.
Despite its efforts, however, Aurora has had a mixed start to the year. The company, like much of the industry, reached a high back in February on a shot of optimism following Biden’s transition to power, but flatlined in recent months, settling at its current price of just $8
Canopy Growth Corporation (NYSE:CGC, TSX:WEED) like many of its peers, started the year off with a bang, rising to nearly $50 in mid-February. That didn’t last long, however, as the industry hype wore off, Canopy came back to earth, settling at today’s prices. Despite this, however, Canopy is still a solid buy in the cannabis industry thanks to its massive partnerships. In fact, just this last year, beverage giant Constellation doubled down on the promising cannabis company once again, investing another $174 million into Canopy, raising its stake to 55.8%.
David Klein, CEO of Canopy Growth, noted “This additional investment validates the work our team has done since attracting the initial investment in 2017. It also strengthens our ability to pursue the immense market and product opportunities available to Canopy in Canada, the US and other key global markets.”
Canopy hasn’t stopped there, however. In addition to its ties to the world’s most influential adult-beverage brand, Canopy is also rubbing shoulders with celebs. In September of 2020, Canopy even teamed up with Martha Stewart to launch a new brand of CBD edibles in a variety of flavors.
Auxly Cannabis Group (TSX.V:XLY) is an up-and-comer in the marijuana industry, with a growing presence in Eastern Canada. The company, formerly known as Cannabis Wheaton, the streaming company operates with a unique spin, focusing on its investments and partnerships within the space.
Some investors are bullish on Auxly due to its rapid rate of growth. And its recent strategic partnership with Atlantic Cultivation solidifies that stance. The company’s streaming business model has been hugely successful in the commodities sector, and it could very well help set Auxly apart in the cannabis realm, as well.
By. Nick Cromwell
**IMPORTANT! BY READING OUR CONTENT YOU EXPLICITLY AGREE TO THE FOLLOWING. PLEASE READ CAREFULLY**
This publication contains forward-looking information which is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ from those projected in the forward-looking statements. Forward looking statements in this publication include that the global wellness market will continue to increase and that demand for mushroom based supplements will continue to rise; that the market for nutraceutical mushroom based products will continue to grow; that the market for psychedelic mushrooms will continue to increase for research purposes focused on alternative mental health treatments; that psychedelics will gain regulatory, medical, commercial and social acceptance as a potential treatment for various mental and other illnesses; that HAVN can be a supplier of functional and psychedelic mushroom products; that HAVN can be a leader in scientific research and achieve a new standard in naturally derived psilocybin; that HAVN can successfully build out supply agreements with researches and obtain supply agreements to create commercialized products; that HAVN will develop fungi-based nutraceutical products for the wellness market that will achieve Health Canada approval and be sold on e-commerce sites and by retailers; that HAVN can produce products using specialized extracts which have a greater therapeutic effect for consumers; that psychedelic mushrooms will be decriminalized and gain acceptance as a viable medical treatment for mental illness; that HAVN will develop a state-of-the-art research lab and become a supplier for the psychedelic and functional mushroom markets; that HAVN is undervalued as a company and may increase in enterprise value in the future. These forward-looking statements are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. Risks that could change or prevent these statements from coming to fruition include that the global wellness market may not increase as anticipated and that demand for supplements, and in particular mushroom based supplements, may decrease; that the market for nutraceutical mushroom based products may decrease; that the market for psychedelic mushrooms decreases psychedelic mushroom based treatments are found to be dangerous, ineffective or have unwanted side effects; that psychedelics will fail to gain regulatory, medical, commercial and social acceptance as a potential treatment for various mental and other illnesses; that HAVN may be unable to develop its business as a supplier of functional and psychedelic mushroom products; that HAVN may fail to become a leader in scientific research or achieve a new standard in naturally derived psilocybin; that HAVN may fail to achieve supply agreements with researches or obtain supply agreements to create any commercialized products; that HAVN may be unable to successfully develop and manufacture fungi-based nutraceutical products for the wellness market that receive Health Canada approval; even if they do successfully produce products, competitors may offer better and cheaper products; that HAVN’s products may prove not to work at all; that psychedelic mushrooms may not be decriminalized or gain only limited or no acceptance as a viable medical treatment for mental illness; that HAVN may be unable to develop a state-of-the-art research lab or become a supplier for the psychedelic and functional mushroom markets; and that HAVN’s enterprise value may not increase as expected or may even decrease in value due to various circumstances. The forward-looking information contained herein is given as of the date hereof and we assume no responsibility to update or revise such information to reflect new events or circumstances, except as required by law.
This communication is for entertainment purposes only. Never invest purely based on our communication. FinancialMorningPost.com and its owners and affiliates (“FinancialMorningPost.com”) are being paid ninety thousand USD for this article as part of a larger marketing campaign for CSE:HAVN. The information in this report and on our website has not been independently verified and is not guaranteed to be correct.
SHARE OWNERSHIP. The owner and affiliates of FinancialMorningPost.com own shares of HAVN and therefore have an additional incentive to see the featured company’s stock perform well. FinancialMorningPost.com is therefore conflicted and is not purporting to present an independent report. The owner and affiliates of FinancialMorningPost.com will not notify the market when it decides to buy more or sell shares of this issuer in the market. The owner of FinancialMorningPost.com will be buying and selling shares of this issuer for its own profit. This is why we stress that you conduct extensive due diligence as well as seek the advice of your financial advisor or a registered broker-dealer before investing in any securities.
NOT AN INVESTMENT ADVISOR. FinancialMorningPost.com is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation, nor are any of its writers or owners.
ALWAYS DO YOUR OWN RESEARCH and consult with a licensed investment professional before making an investment. This communication should not be used as a basis for making any investment.
RISK OF INVESTING. Investing is inherently risky. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell securities. No representation is being made that any stock acquisition will or is likely to achieve profits.psilocybin mushroom psychedelic therapeutics ptsd psychedelics investing investors etf shares tsx cse nasdaq otc mindmed compass havn csehavn laws health canada fda research